Cite
Hellmann MD, Jänne PA, Opyrchal M, et al. Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. Clin Cancer Res. 2020;27(4):1019-1028doi: 10.1158/1078-0432.CCR-20-3305.
Hellmann, M. D., Jänne, P. A., Opyrchal, M., Hafez, N., Raez, L. E., Gabrilovich, D. I., Wang, F., Trepel, J. B., Lee, M. J., Yuno, A., Lee, S., Brouwer, S., Sankoh, S., Wang, L., Tamang, D., Schmidt, E. V., Meyers, M. L., Ramalingam, S. S., Shum, E., & Ordentlich, P. (2021). Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(4), 1019-1028. https://doi.org/10.1158/1078-0432.CCR-20-3305
Hellmann, Matthew D, et al. "Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,4 (2021): 1019-1028. doi: https://doi.org/10.1158/1078-0432.CCR-20-3305
Hellmann MD, Jänne PA, Opyrchal M, Hafez N, Raez LE, Gabrilovich DI, Wang F, Trepel JB, Lee MJ, Yuno A, Lee S, Brouwer S, Sankoh S, Wang L, Tamang D, Schmidt EV, Meyers ML, Ramalingam SS, Shum E, Ordentlich P. Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. Clin Cancer Res. 2021 Feb 15;27(4):1019-1028. doi: 10.1158/1078-0432.CCR-20-3305. Epub 2020 Nov 17. PMID: 33203644; PMCID: PMC7887114.
Copy
Download .nbib